Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VIVIAN CLINE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1003870759
CMS profile
847220
Location
ROUND ROCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,257.45

134 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,257.45 134

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VIVIAN CLINE

NPI 1003870759 · CMS profile ID 847220

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ROUND ROCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003870759?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VIVIAN CLINE, NPI 1003870759, CMS profile ID 847220. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003870759?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). VIVIAN CLINE, NPI 1003870759, CMS profile ID 847220. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003870759?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
VIVIAN CLINE, NPI 1003870759, CMS profile ID 847220, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1003870759?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

134 matching records · $3,257.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 134 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–134 of 134.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $18.6104/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223845609 CMS
PFIZER INC. $16.8404/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228934679 CMS
AstraZeneca Pharmaceuticals LP $24.7504/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206502300 CMS
PUMA BIOTECHNOLOGY, INC. $19.8004/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251745998 CMS
Merck Sharp & Dohme LLC $29.0504/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238309276 CMS
Celgene Corporation $20.6704/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184974996 CMS
TAIHO ONCOLOGY, INC. $25.7104/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211407151 CMS
Daiichi Sankyo Inc. $21.5704/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197059879 CMS
TAIHO ONCOLOGY, INC. $23.2103/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211409792 CMS
AstraZeneca Pharmaceuticals LP $23.9603/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206207540 CMS
Ipsen Biopharmaceuticals, Inc $18.8503/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208832263 CMS
Adaptive Biotechnologies Corporation $20.3203/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254939732 CMS
Ipsen Biopharmaceuticals, Inc $21.2503/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208832265 CMS
Aveo Pharmaceuticals, Inc. $20.8303/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1199899788 CMS
EMD Serono, Inc. $25.7503/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236868816 CMS
GENZYME CORPORATION $20.8803/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233302258 CMS
AstraZeneca Pharmaceuticals LP $25.9603/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207045047 CMS
Celgene Corporation $16.9402/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184974971 CMS
Novartis Pharmaceuticals Corporation $26.7102/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200068148 CMS
Novartis Pharmaceuticals Corporation $6.1602/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200068146 CMS
BeiGene USA, Inc. $25.1102/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202878158 CMS
Regeneron Healthcare Solutions, Inc. $19.3002/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212892498 CMS
Syndax Pharmaceuticals, Inc. $11.9202/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238990536 CMS
Janssen Biotech, Inc. $19.8602/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175123077 CMS
Merck Sharp & Dohme LLC $22.7002/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238222426 CMS
Karyopharm Therapeutics Inc. $22.0902/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246652992 CMS
Eisai Inc. $22.8401/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244518481 CMS
Genmab U.S., Inc. $28.0401/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235929721 CMS
PFIZER INC. $31.7601/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228908090 CMS
Astellas Pharma US Inc $24.4001/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238722526 CMS
E.R. Squibb & Sons, L.L.C. $24.9801/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184974960 CMS
Novartis Pharmaceuticals Corporation $32.3501/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200068142 CMS
Regeneron Healthcare Solutions, Inc. $17.8901/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212892496 CMS
Genentech USA, Inc. $29.9001/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211605721 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $885.66 42
PY2020 $152.68 9
PY2021 $543.07 34
PY2022 $1,972.86 76
PY2023 $2,119.22 80
PY2024 $2,519.61 128
PY2025 $3,257.45 134

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $574,193.92 92
PY2024 Principal investigator $195,287.39 59
PY2023 Principal investigator $88,105.50 15
PY2022 Principal investigator $16,398.74 22
PY2021 Principal investigator $45,749.50 26
PY2020 Principal investigator $13,924.00 13
PY2019 Principal investigator $9,078.00 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

92 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BioNTech SE $1,082.00 12/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013137
Principal investigator 1 Genentech, Inc. $2,500.00 12/12/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675966
Principal investigator 1 BioNTech SE $2,274.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013161
Principal investigator 1 BioNTech SE $293.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013163
Principal investigator 1 BioNTech SE $293.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013165
Principal investigator 1 BioNTech SE $29.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013167
Principal investigator 1 BioNTech SE $2,274.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013193
Principal investigator 1 BioNTech SE $882.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013225
Principal investigator 1 Novartis Pharmaceuticals Corporation $111,196.48 12/02/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY AUSTIN
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3) No dispute reported 06/30/2026 1190298263
Principal investigator 1 ABBVIE INC. $5,100.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202525654
Principal investigator 1 ABBVIE INC. $1,000.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202525656
Principal investigator 1 ABBVIE INC. $2,550.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202525658
Principal investigator 1 ABBVIE INC. $2,550.00 11/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202525664
Principal investigator 1 BioNTech SE $1,501.00 11/20/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013139
Principal investigator 1 BioNTech SE $2,646.00 11/20/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013227
Principal investigator 1 BioNTech SE $6,606.00 11/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013265
Principal investigator 1 Coherus Oncology, Inc. $26,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
CHS11402 No dispute reported 06/30/2026 1235252599
Principal investigator 1 ABBVIE INC. $2,550.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202524231
Principal investigator 1 ABBVIE INC. $1,000.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202524247
Principal investigator 1 ABBVIE INC. $2,550.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202524259
Principal investigator 1 ABBVIE INC. $1,000.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202524261
Principal investigator 1 Genentech, Inc. $2,500.00 11/13/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675952
Principal investigator 1 BioNTech SE $2,274.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013169
Principal investigator 1 BioNTech SE $2,274.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013171
Principal investigator 1 BioNTech SE $293.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013173
Principal investigator 1 BioNTech SE $293.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013175
Principal investigator 1 BioNTech SE $2,274.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013195
Principal investigator 1 BioNTech SE $6,606.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013203
Principal investigator 1 Novartis Pharmaceuticals Corporation $88,768.86 10/27/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY AUSTIN
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3) No dispute reported 06/30/2026 1190298260
Principal investigator 1 Exelixis Inc. $1,500.00 10/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386634
Principal investigator 1 BioNTech SE $1,501.00 10/23/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013141
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,650.24 10/21/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY AUSTIN
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3) No dispute reported 06/30/2026 1190298267
Principal investigator 1 Genentech, Inc. $2,500.00 10/14/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675928
Principal investigator 1 BioNTech SE $9,824.00 10/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT122 No dispute reported 06/30/2026 1249013135
Principal investigator 1 BioNTech SE $882.00 09/18/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013765
Principal investigator 1 Genentech, Inc. $2,500.00 09/05/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675888
Principal investigator 1 ABBVIE INC. $3,500.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202508492
Principal investigator 1 ABBVIE INC. $3,500.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202509924
Principal investigator 1 ABBVIE INC. $18,500.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202509926
Principal investigator 1 ABBVIE INC. $3,500.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202509928
Principal investigator 1 ABBVIE INC. $3,500.00 09/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202509930
Principal investigator 1 BioNTech SE $1,764.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013761
Principal investigator 1 Genentech, Inc. $2,500.00 08/19/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675915
Principal investigator 1 BioNTech SE $293.00 08/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013431
Principal investigator 1 BioNTech SE $293.00 08/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013433
Principal investigator 1 BioNTech SE $293.00 08/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013435
Principal investigator 1 BioNTech SE $293.00 08/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013437
Principal investigator 1 BioNTech SE $2,274.00 08/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013441
Principal investigator 1 BioNTech SE $293.00 08/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013745
Principal investigator 1 BioNTech SE $2,274.00 08/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013747
Principal investigator 1 BioNTech SE $66.00 08/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013755
Principal investigator 1 BioNTech SE $6,606.00 08/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013809
Principal investigator 1 BioNTech SE $2,274.00 07/31/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013443
Principal investigator 1 BioNTech SE $293.00 07/31/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013445
Principal investigator 1 BioNTech SE $2,274.00 07/31/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013447
Principal investigator 1 BioNTech SE $2,274.00 07/31/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013749
Principal investigator 1 BioNTech SE $6,606.00 07/31/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013757
Principal investigator 1 BioNTech SE $2,646.00 07/31/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013767
Principal investigator 1 Exelixis Inc. $1,500.00 07/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386570
Principal investigator 1 Genentech, Inc. $2,500.00 07/21/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675865
Principal investigator 1 BioNTech SE $4,661.00 07/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013731
Principal investigator 1 BioNTech SE $882.00 07/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013763
Principal investigator 1 ABBVIE INC. $19,500.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) No dispute reported 06/30/2026 1202496253
Principal investigator 1 BioNTech SE $4,153.00 06/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013329
Principal investigator 1 BioNTech SE $1,764.00 06/12/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013997
Principal investigator 1 BioNTech SE $6,606.00 06/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013401
Principal investigator 1 Genentech, Inc. $2,500.00 05/19/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675807
Principal investigator 1 BioNTech SE $2,274.00 05/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013421
Principal investigator 1 BioNTech SE $2,274.00 05/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013423
Principal investigator 1 BioNTech SE $2,274.00 05/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013425
Principal investigator 1 BioNTech SE $6,606.00 05/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013427
Principal investigator 1 Ipsen Bioscience Inc. $859.00 05/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176544947
Principal investigator 1 BioNTech SE $882.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013319
Principal investigator 1 BioNTech SE $882.00 04/23/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013317
Principal investigator 1 Genentech, Inc. $2,500.00 04/23/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675828
Principal investigator 1 Novartis Pharmaceuticals Corporation $16.34 04/08/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY AUSTIN
An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer No dispute reported 06/30/2026 1190298272
Principal investigator 1 BioNTech SE $882.00 04/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013315
Principal investigator 1 BioNTech SE $1,082.00 04/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013929
Principal investigator 1 BioNTech SE $882.00 03/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013849
Principal investigator 1 Genentech, Inc. $4,500.00 03/17/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675795
Principal investigator 1 BioNTech SE $1,764.00 03/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013841
Principal investigator 1 BioNTech SE $882.00 03/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013829
Principal investigator 1 Genentech, Inc. $2,500.00 02/14/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675752
Principal investigator 1 BioNTech SE $882.00 02/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013499
Principal investigator 1 Eli Lilly and Company $74,680.00 02/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC No dispute reported 06/30/2026 1187891592
Principal investigator 1 BioNTech SE $6,606.00 02/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT-122-01 No dispute reported 06/30/2026 1249013299
Principal investigator 1 BioNTech SE $6,606.00 02/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013667
Principal investigator 1 Genentech, Inc. $2,500.00 02/04/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675781
Principal investigator 1 BioNTech SE $2,732.00 01/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249014033
Principal investigator 1 Amgen Inc. $3,507.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression No dispute reported 06/30/2026 1246649329
Principal investigator 1 Eli Lilly and Company $7,341.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC No dispute reported 06/30/2026 1187891628
Principal investigator 1 BioNTech SE $882.00 01/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
BNT000-001 No dispute reported 06/30/2026 1249013493